Survey to assess eligibility for infectious disease clinical trials

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

SWIFT-ID-101 is an observational survey designed to evaluate potential participants for eligibility in clinical trials focused on infectious diseases, including HIV and vaccination. Participants will undergo an informed consent process overseen by a physician, followed by a survey covering demographics, medical history, and current health status. Additional assessments may include vital signs, blood tests, and other relevant screenings. The study aims to streamline participant selection for future clinical trials in the field of infectious diseases.

Why it matters

Who can join: the full rules

Inclusion Criteria:

\- 1. Participant or Legally Authorized Representative has signed an ICF prior to study-specific procedures being performed.

2\. Participant is at least 18 years old.

Exclusion Criteria:

1. Participants are pregnant, breast-feeding, or planning to become pregnant.
2. History of a clinically significant illness which in the investigator's opinion may impact participant safety or the ability to analyze study results or makes them unsuitable for the study for another reason.
3. Current or recent moderate or severe substance use disorder impacting their ability to follow study related procedures.
4. Reported history of coagulopathy or bleeding disorder considered a contraindication to phlebotomy.
5. Any condition that in the investigator's opinion makes a participant unsuitable for the clinical trial study.
6. Currently employed by Swift Clinical Research Group, Inc. or any of its subsidiaries, including Brooklyn Clinical Research, or a first-degree relative of an employee.

Where it's running

• Brooklyn Clinical Research
  Brooklyn, New York, United States Recruiting

Study contacts

• Study coordinator: Ammara Mushtaq, MD
• Email: amushtaq@brooklynclinicalresearch.com
• Phone: 9292035879

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Restarting HIV treatment with a single-pill regimen (B/F/TAF) after a treatment gap

  This study tests whether quickly restarting ART with the single-pill regimen B/F/TAF is safe and effective for people with HIV who have had a treatment interruption of at least 12 weeks.

  Recruiting at 10 sites Phase 4 CAN Community Health · Clearwater, Florida and 9 other locations · NCT07476339

• Dengue vaccination strategy for children in the French Caribbean

  This study is trying to see how many children in Martinique and Guadeloupe have been exposed to dengue and whether parents are open to giving them the Dengvaxia® vaccine.

  Recruiting University Hospital Center of Martinique · Fort-de-France · NCT04839757

• RSV vaccine safety and immune response in lung transplant patients vs. healthy adults

  This study tests how well the RSV vaccine works and how safe it is in people who have had a lung transplant compared with healthy adults.

  Recruiting Phase 4 Seoul National University Hospital · Seoul, Jongno-Gu · NCT07895394

• Weekly long-acting HIV-1 meds switch for people with undetectable virus

  This study tests whether switching to weekly oral long-acting HIV medicines works as well as staying on current daily pills for people with HIV who already have an undetectable viral load.

  Recruiting at 2 sites Phase 2 Gilead Sciences · Ft. Pierce, Florida and 1 other locations · NCT07841990

• HIV in Hong Kong: patterns, transmission, and burden over time

  This project tests how HIV-1 infections in Hong Kong have changed over several years by following newly diagnosed adults and analyzing their subtypes, transmission links, and community burden.

  Recruiting Chinese University of Hong Kong · North Point · NCT07725042

• GS-0415 safety and PK in people with HIV on ART

  This study tests GS-0415 in adults with HIV who are on stable ART to see if it is safe, tolerable, and how the drug behaves in the body.

  Recruiting at 15 sites Phase 1 Gilead Sciences · Los Angeles, California and 15 other locations · NCT07719491

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.